Recap - What a week. The iShares NASDAQ Biotechnology (IBB) made new all-time highs and is drastically outpacing the S&P 500, as well as the NASDAQ composite, for the … Continue Reading
Read nowResearch - Bluebird bio (BLUE) develops gene therapy products for diseases with significant unmet needs. Leveraging a proprietary lentiviral gene therapy platform, Bluebird currently has three core clinical … Continue Reading
PremiumInsights - In last week’s biotech recap, and again at PropThink.com this week, we outlined some key support levels for the S&P 500 (SPX or SPY), explaining … Continue Reading
Read nowRecap - The “Hold Your Nose, Buy the Panic” crowd is being vindicated as biotech recovers from a 2-month correction, and makes its way towards old highs. … Continue Reading
Read nowResearch - -TKMR remains an interest at PropThink despite rising 260% since coverage in January. Stock is undervalued relative to peers, has an expanding pipeline, and is … Continue Reading
Read nowInsights - The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns to that of checkpoint inhibitors … Continue Reading
Read nowInsights - One of the names we wrote about back in mid-December as a trade due to its ample cash position and negative enterprise value was Mural … Continue Reading
Premium
